Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...

As the FDA prepares for a busy Oncologic Drugs Advisory Committee next week, an agency insider told BioSpace that volunteers ...

The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals ...

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...